EQ VS SYBX Stock Comparison

Performance

EQ
10/100

EQ returned -70.89% in the last 12 months. Based on SPY's performance of -16.09%, its performance is below average giving it a score of 10 of 100.

SYBX
10/100

SYBX returned -80.37% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

EQ
100/100

2 analysts offer 12-month price targets for EQ. Together, they have an average target of 0, the most optimistic target put EQ at 0 within 12-months and the most pessimistic has EQ at 0.

SYBX
100/100

1 analysts offer 12-month price targets for SYBX. Together, they have an average target of 0, the most optimistic target put SYBX at 0 within 12-months and the most pessimistic has SYBX at 0.

Sentiment

EQ
72/100

EQ had a bullish sentiment score of 71.71% across Twitter and StockTwits over the last 12 months. It had an average of 4.25 posts, 3.92 comments, and 7.17 likes per day.

SYBX
78/100

SYBX had a bullish sentiment score of 77.54% across Twitter and StockTwits over the last 12 months. It had an average of 2.27 posts, 0.18 comments, and 0.73 likes per day.

Technicals

EQ
10/100

EQ receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

SYBX
43/100

SYBX receives a 42 of 100 based on 14 indicators. 5 are bullish, 7 are bearish.

Earnings

EQ
10/100

EQ has missed earnings 8 times in the last 20 quarters.

SYBX
36/100

SYBX has missed earnings 3 times in the last 20 quarters.

Profit

EQ
10/100

Out of the last 20 quarters, EQ has had 1 profitable quarters and has increased their profits year over year on 1 of them.

SYBX
10/100

Out of the last 20 quarters, SYBX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

EQ
34/100

EQ has had a lower than average amount of volatility over the last 12 months giving it a score of 33 of 100.

SYBX
48/100

SYBX has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Equillium, Inc. Common Stock Summary

Nasdaq / EQ

Healthcare

Biotechnology

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Synlogic, Inc. Common Stock Summary

Nasdaq / SYBX

Healthcare

Biotechnology

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Power up your portfolio